Menu Search
Equities

Therma Bright Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TBRIF:QBB

Therma Bright Inc

Actions
  • Price (USD)0.0448
  • Today's Change0.00 / 0.00%
  • Shares traded12.00
  • 1 Year change-78.89%
  • Beta1.5916
Data delayed at least 15 minutes, as of Feb 10 2026 18:23 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Therma Bright Inc. is a Canada-based developer and investment partner specializing in advanced diagnostic and medical device technologies that address key healthcare challenges. The Company is developing, acquiring, manufacturing and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace focused on three key strategic areas: respiratory disease, vascular health and consumer medical devices. Its respiratory disease portfolio includes AI4LYF Digital Cough Technology and InStatin-novel inhaled treatment for asthma and COPD. Its vascular disease portfolio includes Inretio-ischemic stroke treatment and Venowave-Deep Vein Thrombosis Treatment Device (DVT). Its consumer health portfolio consists of AcuVid Covid-19 Rapid Antigen Saliva Test, Benepod-Contrast Therapy Device, TheroZAP-Thermal Therapy Device and InterceptCS-Cold Sore Prevention System. The Company holds trademarks for Therozap, InterceptCS and AcuVid.

  • Revenue in CAD (TTM)75.23k
  • Net income in CAD-4.16m
  • Incorporated2018
  • Employees--
  • Location
    Therma Bright Inc345 Danforth AvenueTORONTO M4K 1N7CanadaCAN
  • Phone+1 (416) 867-2353
  • Fax+1 (416) 867-4566
  • Websitehttps://thermabright.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.